glp-1 receptor agonist antipsychotic weight gain study New Loss Drugs in Psychiatry Efficacy and Safety of GLP-1

Int J Mol Sci (2023) 24(4):3140

Early biosimilar pipelines now coincide with once-weekly and dual-incretin innovations, encouraging payers to re-examine cost-effectiveness thresholds and to broaden indication coverage beyond glycemic control

While pancreatitis remains a warning on product labeling and a theoretical concern due to shared pathways, large-scale CVOTs and subsequent meta-analyses have not shown a statistically significant increase in the risk of acute pancreatitis compared to placebo [86]

The stimulation of GLP-1R, however, may also elicit adverse events

Shares of Novo Nordisk gained roughly 10% in extended trading Monday